Hair loss has been reported by around 5-6% of people taking tirzepatide (Mounjaro) at the highest dose in clinical trials, compared with roughly 1% on placebo, and it affects women more often than men — around 7% versus under 1%. The mechanism is almost always telogen effluvium, a well-understood, temporary shedding pattern triggered by rapid weight loss or significant metabolic change, rather than a direct toxic effect on hair follicles. It typically begins 2 to 4 months after starting treatment or a significant weight change, and resolves within 6 to 12 months for most people once weight stabilises. Adequate protein and micronutrient intake, and not restricting calories more aggressively than necessary, are the most evidence-backed ways to support your hair through this period.
In the SURMOUNT-1 trial evaluating tirzepatide for weight management, alopecia (hair loss) was reported as an adverse event in approximately 5.7% of participants at the highest dose studied, compared with roughly 0.9% in the placebo group — a meaningful difference that confirms this is a genuine, documented effect rather than coincidence. A separate large real-world database study covering nearly 9,000 participants over two years found a similar pattern, with around 5.7% experiencing alopecia.
The gender difference is consistently reported across multiple studies: women experience hair loss at notably higher rates than men, with some data showing rates approaching 7% in women compared with under 1% in men. This is likely linked to hormonal sensitivity and the fact that women are statistically more likely to notice and report changes in hair volume, though the underlying biological trigger — rapid weight loss — affects both sexes.
Why It Happens: Telogen Effluvium ExplainedThe leading explanation for GLP-1-related hair loss is a condition called telogen effluvium, and understanding it helps explain why the timing and pattern are so predictable. Under normal conditions, around 85-90% of your hair follicles are in the anagen (active growth) phase at any given time, with the rest resting or shedding as part of a normal cycle. When the body experiences a significant physical stressor — rapid weight loss, a major calorie deficit, illness, or significant metabolic change — it can prematurely push a large number of follicles into the telogen (resting) phase all at once.
Those hairs don't fall out immediately. They sit in the resting phase for roughly 2 to 4 months before shedding, which is exactly why hair loss on Mounjaro typically appears a few months after starting treatment or after a period of particularly rapid weight loss, rather than immediately when you begin.
Worth knowing
This same pattern of hair loss occurs with rapid weight loss achieved through any method — bariatric surgery, intensive dieting, or illness — not just GLP-1 medicines. Studies of bariatric surgery patients have documented hair loss in 30-50% of cases, generally at a higher rate than seen with GLP-1 medicines, which is useful context for understanding that this is a response to the rate of weight loss itself, not something unique or alarming about Mounjaro specifically.
Reduced appetite means many people on Mounjaro are eating significantly less overall, which can create genuine nutritional gaps that compound telogen effluvium if not addressed.
- Protein: hair is largely made of keratin, a protein, and inadequate protein intake directly limits the raw material your body needs for hair growth
- Iron: low ferritin (iron stores) is consistently associated with telogen effluvium, particularly in women, and calorie restriction is a well-documented cause of declining ferritin levels
- Zinc: deficiency impairs keratin production and follicle protein synthesis
- Biotin and other B vitamins: while less strongly evidenced than protein, iron and zinc, deficiencies can still contribute to a generally less supportive environment for hair growth
For a fuller breakdown of protein targets and micronutrients to watch during GLP-1 treatment, see our dedicated nutrition guide covering Mounjaro and Wegovy.
What Genuinely HelpsPrioritise Protein at Every Meal
Given hair's composition, adequate protein intake is the single most directly relevant nutritional factor. Clinical guidance for GLP-1 treatment generally recommends higher protein intake than the standard baseline — around 1.2 to 1.6g per kilogram of body weight daily — partly to protect muscle mass, but this same principle supports hair health too.
Don't Restrict More Aggressively Than Your Appetite Naturally Suggests
Mounjaro's appetite suppression already creates a significant calorie deficit for most people. Adding further deliberate restriction on top of this can push your body into a more severe stress response, potentially worsening telogen effluvium. Eating to genuine fullness within your reduced appetite, rather than restricting further, is generally the better approach.
Consider Your Micronutrient Intake
If your diet has become quite limited, a standard multivitamin may be reasonable, but avoid high-dose individual supplements without medical advice — particularly iron, since excess iron intake can be harmful. If you're concerned about specific deficiencies, ask your GP about a blood test to check ferritin and other relevant markers before starting supplementation.
Be Patient
Because of the 2-4 month delay between the triggering stress and visible shedding, and the further months needed for regrowth, telogen effluvium can take up to a year to fully resolve from start to finish. This is genuinely difficult to sit with, but stopping Mounjaro specifically because of hair loss rarely accelerates recovery, since the underlying trigger (recent rapid weight loss) has often already occurred by the time shedding becomes noticeable.
If you already have androgenetic alopecia (male or female pattern hair loss) before starting Mounjaro, it can sometimes be difficult to distinguish new telogen effluvium from your existing pattern progressing on its own. Interestingly, a small number of case reports have even described improved hair density in some people with androgenetic alopecia after months on tirzepatide, with researchers proposing that improved insulin sensitivity may play a role — though this remains anecdotal rather than established evidence, and shouldn't be read as a reason to expect improvement. If you have a pre-existing hair condition, mentioning this at your consultation helps your prescriber interpret any changes you notice more accurately.
When to See a DoctorMost Mounjaro-related hair loss follows the pattern described above and doesn't require medical intervention beyond nutritional support. However, it's worth seeing your GP if:
- Hair loss is patchy rather than diffuse (spread evenly across the scalp), which can suggest a different underlying cause
- You notice scalp changes, redness, or scarring alongside the hair loss
- Shedding hasn't started to improve after 12 months
- You have other symptoms alongside hair loss that could suggest an unrelated cause, such as significant fatigue or menstrual changes
Important
Never stop Mounjaro abruptly because of hair loss without discussing it with your prescriber first. Your prescriber can help assess whether nutritional support, a slower rate of weight loss, or blood tests to check for deficiencies are the right next step, rather than discontinuing treatment altogether.
Concerned About Side Effects? We're Here to Help.
Our GPhC-registered pharmacy team can talk through any side effects you're experiencing on Mounjaro, including practical nutritional support to help protect your hair and general health during treatment.
Start Your Free Online Consultation → Use code SWITCH10 if you're switching from another providerHappy Pharmacy is a GPhC-registered pharmacy (No. 9012585) — Superintendent Pharmacist: Palvinder Deol — Rated 4.8★ Excellent on Trustpilot
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022.
- Increased risk of telogen effluvium with tirzepatide compared with other weight loss medications: a retrospective cohort study.
- Hair Loss Associated With Glucagon-Like Peptide-1 (GLP-1) Receptor Agonist Use: A Systematic Review.
- Mounjaro® (tirzepatide) UK Summary of Product Characteristics.